The Raymond James Financial Services Advisors Inc. Purchases 2,871 Shares of Alexion Pharmaceuticals, Inc. (ALXN)

The Raymond James Financial Services Advisors Inc. Purchases 2,871 Shares of Alexion Pharmaceuticals, Inc. (ALXN)

Raymond James Financial Services Advisors Inc. increased its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 9.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 34,782 shares of the biopharmaceutical company’s stock after acquiring an additional 2,871 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Alexion Pharmaceuticals were worth $4,232,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently made changes to their positions in the stock. BlackRock Inc. raised its holdings in shares of Alexion Pharmaceuticals by 7.0% during the second quarter. BlackRock Inc. now owns 19,926,265 shares of the biopharmaceutical company’s stock worth $2,424,428,000 after acquiring an additional 1,298,185 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Alexion Pharmaceuticals by 2.2% during the second quarter. Vanguard Group Inc. now owns 14,785,831 shares of the biopharmaceutical company’s stock worth $1,798,992,000 after acquiring an additional 318,375 shares in the last quarter. State Street Corp raised its holdings in shares of Alexion Pharmaceuticals by 5.0% during the second quarter. State Street Corp now owns 11,860,647 shares of the biopharmaceutical company’s stock worth $1,443,099,000 after acquiring an additional 561,962 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in shares of Alexion Pharmaceuticals by 0.4% during the second quarter. Ameriprise Financial Inc. now owns 6,175,296 shares of the biopharmaceutical company’s stock worth $751,363,000 after acquiring an additional 25,724 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in shares of Alexion Pharmaceuticals by 2.0% during the second quarter. Bank of New York Mellon Corp now owns 3,349,821 shares of the biopharmaceutical company’s stock worth $407,573,000 after acquiring an additional 64,800 shares in the last quarter. Institutional investors and hedge funds own 94.25% of the company’s stock.

Alexion Pharmaceuticals, Inc. (ALXN) traded down 0.60% during midday trading on Friday, reaching $140.61. The company had a trading volume of 721,653 shares. The firm has a market capitalization of $31.38 billion, a P/E ratio of 60.98 and a beta of 1.39. Alexion Pharmaceuticals, Inc. has a one year low of $96.18 and a one year high of $149.34. The stock’s 50 day moving average price is $142.11 and its 200-day moving average price is $127.08.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 EPS for the quarter, beating the Zacks’ consensus estimate of $1.08 by $0.48. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The business had revenue of $912.00 million for the quarter, compared to analyst estimates of $846.15 million. During the same quarter in the prior year, the business earned $1.13 EPS. Alexion Pharmaceuticals’s quarterly revenue was up 21.1% on a year-over-year basis. On average, equities research analysts anticipate that Alexion Pharmaceuticals, Inc. will post $5.60 earnings per share for the current year.

Several analysts recently issued reports on the company. Zacks Investment Research lowered Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, October 2nd. Leerink Swann reiterated a “buy” rating and set a $182.00 price objective on shares of Alexion Pharmaceuticals in a report on Monday, September 25th. Royal Bank Of Canada assumed coverage on Alexion Pharmaceuticals in a report on Thursday, September 14th. They set an “outperform” rating and a $161.00 price objective for the company. Deutsche Bank AG reiterated a “buy” rating and set a $158.00 price objective (up from $153.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, September 13th. Finally, SunTrust Banks, Inc. reiterated a “buy” rating and set a $180.00 price objective (up from $170.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, September 13th. Six analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have assigned a strong buy rating to the company. Alexion Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $154.56.

In other Alexion Pharmaceuticals news, Director Ann M. Veneman sold 835 shares of the stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $145.81, for a total transaction of $121,751.35. Following the transaction, the director now owns 5,480 shares in the company, valued at approximately $799,038.80. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Ann M. Veneman sold 700 shares of the stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $137.74, for a total transaction of $96,418.00. Following the transaction, the director now owns 6,315 shares in the company, valued at approximately $869,828.10. The disclosure for this sale can be found here. In the last quarter, insiders sold 17,190 shares of company stock worth $2,433,669. 4.35% of the stock is owned by company insiders.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Related posts

Leave a Comment